Last Price
0.919
Today's Change
-0.004 (0.43%)
Day's Change
0.895 - 0.935
Trading Volume
811,466
Market Cap
40 Million
Shares Outstanding
43 Million
Avg Volume
3,136,634
Avg Price (50 Days)
0.90
Avg Price (200 Days)
1.94
PE Ratio
-0.60
EPS
-1.53
Earnings Announcement
17-Mar-2025
Previous Close
0.92
Open
0.94
Day's Range
0.895 - 0.935
Year Range
0.699 - 6.0
Trading Volume
811,466
1 Day Change
-0.39%
5 Day Change
-6.23%
1 Month Change
14.86%
3 Month Change
-14.12%
6 Month Change
-58.79%
Ytd Change
7.05%
1 Year Change
-78.38%
3 Year Change
-77.64%
5 Year Change
-99.25%
10 Year Change
-99.99%
Max Change
-99.95%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.